Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?

RXRX gears up for Q4 with $25.5 million revenue view as investors eye pipeline updates and REC-4881 progress ahead of FDA ...

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of ...